Compare · NVO vs STTK
NVO vs STTK
Side-by-side comparison of Novo Nordisk A/S (NVO) and Shattuck Labs Inc. (STTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and STTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 266.4x STTK ($808.9M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for STTK).
- NVO has more recent analyst coverage (25 ratings vs 15 for STTK).
- Company
- Novo Nordisk A/S
- Shattuck Labs Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $808.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 15
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Shattuck Labs Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest STTK
- Raymond James initiated coverage on Shattuck Labs with a new price target
- SEC Form S-8 filed by Shattuck Labs Inc.
- Shattuck Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Shattuck Labs Inc.
- Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Leerink Partners initiated coverage on Shattuck Labs with a new price target
- Amendment: SEC Form SCHEDULE 13D/A filed by Shattuck Labs Inc.
- Chief Technical Officer Shukla Abhinav A. exercised 12,563 shares at a strike of $3.57 and sold $2,874 worth of shares (410 units at $7.01) as part of a pre-agreed trading plan, increasing direct ownership by 14% to 98,533 units (SEC Form 4) to satisfy withholding obligation
- Chief Technical Officer Shukla Abhinav A. exercised 23,465 shares at a strike of $3.57 and sold $166,131 worth of shares (23,465 units at $7.08) as part of a pre-agreed trading plan (SEC Form 4) (for tax liability)
- Chief Medical Officer Pandite Arundathy N. sold $210,300 worth of shares (30,000 units at $7.01) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 136,219 units (SEC Form 4)